Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Harvard Business School
Dow
McKesson
Johnson and Johnson

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Telotristat ethyl

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Telotristat ethyl?

Telotristat ethyl is an investigational drug.

There have been 11 clinical trials for Telotristat ethyl. The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2020.

The most common disease conditions in clinical trials are Malignant Carcinoid Syndrome, Serotonin Syndrome, and Neuroendocrine Tumors. The leading clinical trial sponsors are Lexicon Pharmaceuticals, Ipsen, and National Cancer Institute (NCI).

There are twelve US patents protecting this investigational drug and one hundred and nine international patents.

Recent Clinical Trials for Telotristat ethyl
TitleSponsorPhase
Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic CancerLexicon PharmaceuticalsPhase 2
Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic CancerEmory UniversityPhase 2
Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid SyndromeIpsenPhase 3

See all Telotristat ethyl clinical trials

Clinical Trial Summary for Telotristat ethyl

Top disease conditions for Telotristat ethyl
Top clinical trial sponsors for Telotristat ethyl

See all Telotristat ethyl clinical trials

US Patents for Telotristat ethyl

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Telotristat ethyl   Start Trial Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase ACTELION PHARMACEUTICALS LTD (Allschwil, CH)   Start Trial
Telotristat ethyl   Start Trial 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use Lexicon Pharmaceuticals, Inc. (The Woodlands, TX)   Start Trial
Telotristat ethyl   Start Trial 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use Lexicon Pharmaceuticals, Inc. (The Woodlands, TX)   Start Trial
Telotristat ethyl   Start Trial Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds Lexicon Pharmaceuticals, Inc. (The Woodlands, TX)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Telotristat ethyl

Drugname Country Document Number Estimated Expiration Related US Patent
Telotristat ethyl Canada 2927121 2033-11-19   Start Trial
Telotristat ethyl China 105745211 2033-11-19   Start Trial
Telotristat ethyl European Patent Office 3071567 2033-11-19   Start Trial
Telotristat ethyl Spain 2650921 2033-11-19   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Moodys
AstraZeneca
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.